Arcus Biosciences (RCUS) Price & Analysis

Compare

535 Followers

RCUS Stock Chart & Stats

$22.28

-$0.04(-0.26%)

At close: Jan 08 4:00 PM EST

$22.28

-$0.04(-0.26%)

Day’s Range― - ―

52-Week Range$6.50 - $26.40

Previous CloseN/A

Volume107.84K

Average Volume (3M)1.94M

Market Cap

$2.75B

Enterprise Value$728.40M

Total Cash (Recent Filing)$831.00M

Total Debt (Recent Filing)$111.00M

Price to Earnings (P/E)―

Beta2.03

Next Earnings

Feb 25, 2026

EPS Estimate

-1.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.27

Shares Outstanding123,728,540

10 Day Avg. Volume2,591,816

30 Day Avg. Volume1,938,630

Financial Highlights & Ratios

PEG Ratio0.19

Price to Book (P/B)2.77

Price to Sales (P/S)5.20

P/FCF Ratio-7.62

Enterprise Value/Market Cap0.27

Enterprise Value/Revenue3.04

Enterprise Value/Gross Profit3.06

Enterprise Value/Ebitda-2.26

Forecast

1Y Price Target

$27.78

Price Target Upside24.69% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

EPS Forecast (FY)-3.59

Revenue Forecast (FY)$247.89M

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe recent strong Ph2 EDGE-Gastric data showed mOS double the standard of care.

Financial ResourcesWith approximately $1B in cash and investments, RCUS expects to fund planned operations into at least 2H28, providing runway to advance casdatifan through key clinical stages.

Pipeline DevelopmentThe unveiling of five early-stage programs in autoimmune and inflammatory diseases indicates a strong pipeline and future growth potential.

Bears Say

Investor UncertaintyThere’s more investor uncertainties over whether the team can achieve its expansive commercial plans in RCC due to a fragmented market and lack of a commercial partner.

Program DiscontinuationArcus plans to discontinue dom's development in GI cancer, and it is expected that dom's ongoing NSCLC studies might eventually be discontinued as well.

Trial DiscontinuationThe Ph3 STAR-221 trial has been discontinued due to futility observed at a pre-specified interim OS analysis in 1L HER2-negative advanced gastric-and-esophageal cancer.

Arcus Biosciences News

Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

Investors seeking all of the latest and greats stock market stories for Friday will find them in our daily roundup. ...

6d ago

AMD

LLY

Arcus Biosciences price target lowered to $44 from $56 at Citi

Citi analyst Yigal Nochomovitz lowered the firm’s price target on Arcus Biosciences (RCUS) to $44 from $56 and...

6d ago

RCUS

Arcus Biosciences price target lowered to $30 from $39 at Truist

Truist lowered the firm’s price target on Arcus Biosciences (RCUS) to $30 from $39 and keeps a Buy...

7d ago

RCUS

Arcus Biosciences price target raised to $32 from $28 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Arcus Biosciences (RCUS) to $32 from $28 and keeps a...

7d ago

RCUS

Arcus Biosciences falls -11.2%

Arcus Biosciences (RCUS) is down -11.2%, or -$2.81 to $22.33. Published first on TheFly – the ultimate source...

7d ago

RCUS

Arcus Biosciences Stock (RCUS) Collapses 17% after Failed Stomach Cancer Study

Shares in biopharmaceutical company Arcus Biosciences ($RCUS) collapsed 17% in pre-market trading after it said it was stopping...

7d ago

BMY

GILD

Arcus Biosciences announces discontinuation of STAR-221 study

Arcus Biosciences (RCUS) announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead...

7d ago

GILD

RCUS

Arcus Biosciences price target raised to $26 from $17 at BofA

BofA raised the firm’s price target on Arcus Biosciences (RCUS) to $26 from $17 and keeps a Neutral...

21d ago

RCUS

Arcus Biosciences Amends Loan Facility, Extends Maturity Terms

Arcus Biosciences ( ($RCUS) ) has issued an update. On December 18, 2025, Arcus Biosciences amended its existing...

11h ago

RCUS

Arcus Biosciences: Strategic Shift to Casdatifan with Strong Financial Position and Buy Rating

Analyst Asthika Goonewardene from Truist Financial maintained a Buy rating on Arcus Biosciences and decreased the price target...

7d ago

RCUS

Arcus Biosciences: Strategic Focus and Financial Positioning Drive Buy Rating

Analyst Emily Bodnar from H.C. Wainwright reiterated a Buy rating on Arcus Biosciences and increased the price target...

7d ago

RCUS

Arcus Biosciences Ends Phase 3 STAR-221 Study

Arcus Biosciences ( ($RCUS) ) has provided an announcement. On December 12, 2025, Arcus Biosciences announced the discontinuation...

7d ago

RCUS

Arcus Biosciences Completes Successful Stock Offering

Arcus Biosciences ( ($RCUS) ) just unveiled an update. Arcus Biosciences, Inc. recently completed a public offering of...

2M ago

RCUS

Arcus Biosciences 13.7M share Spot Secondary priced at $18.25

The deal range was $18.25-$18.75. Leerink and Goldman Sachs acted as joint book running managers for the offering....

2M ago

RCUS

RCUS FAQ

What was Arcus Biosciences Inc’s price range in the past 12 months?

Arcus Biosciences Inc lowest stock price was $6.50 and its highest was $26.40 in the past 12 months.

What is Arcus Biosciences Inc’s market cap?

Arcus Biosciences Inc’s market cap is $2.75B.

When is Arcus Biosciences Inc’s upcoming earnings report date?

Arcus Biosciences Inc’s upcoming earnings report date is Feb 25, 2026 which is in 68 days.

How were Arcus Biosciences Inc’s earnings last quarter?

Arcus Biosciences Inc released its earnings results on Oct 28, 2025. The company reported -$1.27 earnings per share for the quarter, beating the consensus estimate of -$1.31 by $0.04.

Is Arcus Biosciences Inc overvalued?

According to Wall Street analysts Arcus Biosciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Arcus Biosciences Inc pay dividends?

Arcus Biosciences Inc does not currently pay dividends.

What is Arcus Biosciences Inc’s EPS estimate?

Arcus Biosciences Inc’s EPS estimate is -1.13.

How many shares outstanding does Arcus Biosciences Inc have?

Arcus Biosciences Inc has 123,728,540 shares outstanding.

What happened to Arcus Biosciences Inc’s price movement after its last earnings report?

Arcus Biosciences Inc reported an EPS of -$1.27 in its last earnings report, beating expectations of -$1.31. Following the earnings report the stock price went up 2.062%.

Which hedge fund is a major shareholder of Arcus Biosciences Inc?

Currently, no hedge funds are holding shares in RCUS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Arcus Biosciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-68.13%

Trailing 12-Months

Asset Growth

-22.20%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Arcus Biosciences (RCUS) Earnings & Revenues

Historic Earnings Reports

RCUS Stock 12 Month Forecast

Average Price Target

$27.78

▲(24.69% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","45":"$45","15.75":"$15.75","25.5":"$25.5","35.25":"$35.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$44.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$27.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,15.75,25.5,35.25,45],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.1,27.47692307692308,28.853846153846156,30.230769230769234,31.60769230769231,32.98461538461539,34.36153846153846,35.738461538461536,37.11538461538461,38.49230769230769,39.86923076923077,41.246153846153845,42.62307692307692,{"y":44,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.1,26.22923076923077,26.35846153846154,26.48769230769231,26.61692307692308,26.74615384615385,26.87538461538462,27.004615384615384,27.133846153846154,27.263076923076923,27.392307692307693,27.521538461538462,27.65076923076923,{"y":27.78,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.1,25.169230769230772,24.23846153846154,23.30769230769231,22.376923076923077,21.446153846153848,20.515384615384615,19.584615384615386,18.653846153846153,17.723076923076924,16.792307692307695,15.861538461538462,14.930769230769231,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.94,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.89,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.71,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.81,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.72,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >